Vanguard Personalized Indexing Management
HRTX icon

Vanguard Personalized Indexing Management’s Heron Therapeutics HRTX Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.6K Buy
27,276
+13,848
+103% +$11.1K ﹤0.01% 2228
2026
Q1 		$10.7K Sell
13,428
-1,468
-10% -$1.7K ﹤0.01% 2152
2025
Q4 		$19.4K Buy
14,896
+75
+0.5% +$93 ﹤0.01% 1941
2025
Q3 		$18.7K Sell
14,821
-898
-6% -$1.42K ﹤0.01% 1966
2025
Q2 		$32.5K Sell
15,719
-40
-0.3% -$82 ﹤0.01% 1867
2025
Q1 		$34.7K Sell
15,759
-18
-0.1% -$35 ﹤0.01% 1713
2024
Q4 		$24.1K Buy
15,777
+2,639
+20% +$4.28K ﹤0.01% 1755
2024
Q3 		$26.1K Sell
13,138
-136
-1% -$325 ﹤0.01% 1726
2024
Q2 		$46.5K Buy
13,274
+136
+1% +$418 ﹤0.01% 1593
2024
Q1 		$36.4K Hold
13,138
– – ﹤0.01% 1582
2023
Q4 		$22.3K Buy
+13,138
New +$14.5K ﹤0.01% 1545

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Vanguard Personalized Indexing Management's HRTX Position: Q2 2026 in Review

Vanguard Personalized Indexing Management increased its Heron Therapeutics (HRTX) stake by 103% in Q2 2026, buying an estimated $11.1K and bringing the position to 27,276 shares worth $11.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2228.

Vanguard Personalized Indexing Management first reported a position in HRTX in Q4 2023 and has held it in 11 quarters since. The position peaked at $46.5K in Q2 2024. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Vanguard Personalized Indexing Management held 27,276 shares of Heron Therapeutics worth $11.6K as of Q2 2026.
  • Vanguard Personalized Indexing Management bought 13,848 Heron Therapeutics shares in Q2 2026, an estimated $11.1K.
  • Heron Therapeutics made up ﹤0.01% of Vanguard Personalized Indexing Management's portfolio in Q2 2026, its #2228 holding.
  • Vanguard Personalized Indexing Management first reported a position in Heron Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Vanguard Personalized Indexing Management's Heron Therapeutics position peaked at $46.5K in Q2 2024.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q2 2026, filed 11 Aug 2026.